- Home
- MGN vs ATNM Comparison
MGN vs ATNM Comparison
Compare MGN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | ATNM |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 50.2M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGN | ATNM |
|---|---|---|
| Price | $2.12 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 52.5K | ★ 204.3K |
| Earning Date | 12-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $13,484,571.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | $29.72 | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.30 | $1.03 |
| 52 Week High | $8.63 | $2.41 |
Technical Indicators
Market Signals| Indicator | MGN | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.42 |
| Support Level | N/A | $1.33 |
| Resistance Level | N/A | $1.54 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 51.43 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.